MX365484B - Anticuerpo monoclonal que inhibe la actividad enzimatica de la lipasa endotelial. - Google Patents

Anticuerpo monoclonal que inhibe la actividad enzimatica de la lipasa endotelial.

Info

Publication number
MX365484B
MX365484B MX2015011923A MX2015011923A MX365484B MX 365484 B MX365484 B MX 365484B MX 2015011923 A MX2015011923 A MX 2015011923A MX 2015011923 A MX2015011923 A MX 2015011923A MX 365484 B MX365484 B MX 365484B
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
enzymatic activity
endothelial lipase
antibody inhibiting
inhibiting enzymatic
Prior art date
Application number
MX2015011923A
Other languages
English (en)
Other versions
MX2015011923A (es
Inventor
Takahashi Tatsuya
Naito Shoichi
Onoda Junji
Tsukamoto Tasuku
Yamada Katsutoshi
Yamane Shoji
Numata Yoshito
Maekawa Kazuhiko
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51536833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX365484(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2015011923A publication Critical patent/MX2015011923A/es
Publication of MX365484B publication Critical patent/MX365484B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal o uno de sus fragmentos que son efectivos en el tratamiento de arteriosclerosis y síndrome metabólico y selectivamente inhiben la actividad de la lipasa endotelial, y una composición farmacéutica que incluye esta misma como un componente activo.
MX2015011923A 2013-03-14 2014-03-12 Anticuerpo monoclonal que inhibe la actividad enzimatica de la lipasa endotelial. MX365484B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013051995 2013-03-14
PCT/JP2014/056526 WO2014142182A1 (ja) 2013-03-14 2014-03-12 血管内皮リパーゼの酵素活性を阻害するモノクローナル抗体

Publications (2)

Publication Number Publication Date
MX2015011923A MX2015011923A (es) 2015-12-01
MX365484B true MX365484B (es) 2019-06-05

Family

ID=51536833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011923A MX365484B (es) 2013-03-14 2014-03-12 Anticuerpo monoclonal que inhibe la actividad enzimatica de la lipasa endotelial.

Country Status (17)

Country Link
US (3) US9701757B2 (es)
EP (1) EP2975060A4 (es)
JP (1) JP6304775B2 (es)
KR (1) KR102034478B1 (es)
CN (1) CN105377896B (es)
AU (1) AU2014230640B2 (es)
BR (1) BR112015022009A2 (es)
CA (1) CA2905597C (es)
CL (1) CL2015002642A1 (es)
IL (1) IL241097B (es)
MX (1) MX365484B (es)
MY (1) MY166357A (es)
PH (1) PH12015502092A1 (es)
RU (1) RU2662673C2 (es)
SG (2) SG11201507105RA (es)
WO (1) WO2014142182A1 (es)
ZA (1) ZA201506536B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI688575B (zh) * 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
IL256295B2 (en) * 2015-06-30 2023-11-01 Seagen Inc Anti-NTB-A antibodies and related compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
NZ514350A (en) 1999-03-26 2004-12-24 Aventis Pharma Inc Compositions and methods for effecting the levels of cholesterol
AU2005334672A1 (en) * 2005-07-21 2007-01-25 Reliance Life Sciences Pvt Ltd Compounds for treatment of lipase-mediated diseases
US9296825B2 (en) 2011-10-12 2016-03-29 Shionogi & Co., Ltd. Monoclonal antibody against EL which inhibits enzyme activity of EL

Also Published As

Publication number Publication date
WO2014142182A1 (ja) 2014-09-18
BR112015022009A2 (pt) 2017-08-29
SG11201507105RA (en) 2015-10-29
JP6304775B2 (ja) 2018-04-04
US20190211114A1 (en) 2019-07-11
RU2662673C2 (ru) 2018-07-26
IL241097B (en) 2018-10-31
KR20150127248A (ko) 2015-11-16
MX2015011923A (es) 2015-12-01
IL241097A0 (en) 2015-11-30
MY166357A (en) 2018-06-25
CA2905597C (en) 2019-09-24
PH12015502092A1 (en) 2016-01-18
US20170275378A1 (en) 2017-09-28
EP2975060A4 (en) 2017-02-22
CA2905597A1 (en) 2014-09-18
RU2015143477A (ru) 2017-04-20
JPWO2014142182A1 (ja) 2017-02-16
US10745491B2 (en) 2020-08-18
CN105377896B (zh) 2020-06-23
EP2975060A1 (en) 2016-01-20
CN105377896A (zh) 2016-03-02
US9701757B2 (en) 2017-07-11
KR102034478B1 (ko) 2019-10-21
AU2014230640B2 (en) 2018-08-16
US20160009819A1 (en) 2016-01-14
AU2014230640A1 (en) 2015-09-17
CL2015002642A1 (es) 2016-03-18
US10239955B2 (en) 2019-03-26
ZA201506536B (en) 2017-11-29
SG10201707233UA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
BR112015013123A2 (pt) inibidores de beta-lactamase
PH12017500461A1 (en) Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
UY34395A (es) ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?.
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
MX2023010206A (es) Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
MX337248B (es) Variantes de plasminogeno y plasmina.
UY34676A (es) ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CL2015001640A1 (es) Heterociclos n-acetilados y de nitrógeno saturados que potencian la actividad de un antibiótico activo contra micobacterias
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX2017002323A (es) Variantes de desintegrina y usos farmaceuticos de las mismas.
EA201590796A1 (ru) Фибринолитические композиции, включающие бромелаин и наттокиназу, для предотвращения и лечения флеботромботических состояний
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
PH12015502092A1 (en) Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
EA201600012A1 (ru) Способ профилактики и/или лечения сердечно-сосудистых заболеваний
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2013342779A8 (en) Anti-ADAM28 antibody for treating cancer
TR201722950A2 (tr) Koah tedavisinde yeni farmasötik bileşimler.
UA97245U (en) Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin

Legal Events

Date Code Title Description
FG Grant or registration